Compare DVN & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DVN | TAK |
|---|---|---|
| Founded | 1971 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.0B | 57.6B |
| IPO Year | 1999 | 2007 |
| Metric | DVN | TAK |
|---|---|---|
| Price | $49.52 | $18.72 |
| Analyst Decision | Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $50.15 | N/A |
| AVG Volume (30 Days) | ★ 9.7M | 2.1M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | 1.88% | ★ 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.60 | N/A |
| Revenue | ★ $17,188,000,000.00 | N/A |
| Revenue This Year | $28.91 | $0.16 |
| Revenue Next Year | $8.55 | $1.22 |
| P/E Ratio | ★ $19.81 | $41.25 |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $31.47 | $12.99 |
| 52 Week High | $52.71 | $18.90 |
| Indicator | DVN | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 69.48 | 64.39 |
| Support Level | $41.93 | $17.87 |
| Resistance Level | $52.33 | $18.85 |
| Average True Range (ATR) | 1.16 | 0.21 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 96.39 | 84.66 |
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two-thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. After the merger with Coterra, it will have a foothold in the gas-driven Appalachian Basin as well. At the end of 2025, Devon reported net proved reserves of 2.4 billion barrels of oil equivalent, up from 2.2 billion in 2024. Net production averaged roughly 840,000 barrels of oil equivalent per day in 2025 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.